Evidence map›Paper›PMID 40170133›Full record

ArticleJournal of translational medicine2025

CircPRKCA facilitates esophageal squamous cell carcinoma metastasis via m5C-dependent CSF2 mRNA stabilization.

Lixia Wu, Lina Gu, Yang Zheng, Jingjing Liu, Zishuan Wei, Fei Liu, Jiali Li, Lingjiao Meng, Yang Sang, Meixiang Sang and 2 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. mBiology direct · 2026
    Review
  4. Review
  5. Article
  6. Recent advances of circular RNAs in gastrointestinal cancer.World journal of clinical oncology · 2025
    Review
  7. NSUN2-mediated m5C hypermethylation ofNon-coding RNA research · 2025
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lixia Wu *Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Lina Gu *Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Yang ZhengResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Jingjing LiuResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Zishuan WeiResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Fei LiuResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Jiali LiResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Lingjiao MengResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Yang SangAnimal Care and Use Committee of the Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Meixiang SangShanghai Electric Power Hospital, Shanghai, 200050, China.
Lianmei ZhaoResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China. lianmei555@hebmu.edu.cn.
Baoen ShanResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China. 462000595@hebmu.edu.cn.

Funding

National Natural Science Foundation of China U21A20415Natural Science Foundation of Hebei Province H2022206525
6 · The paper itself

Abstract

backgroundEsophageal squamous cell carcinoma (ESCC) is a serious invasive malignancy with an ambiguous etiology. Evidence indicates that circular RNA (circRNA) is significantly involved in the regulatory processes associated with cancer development. Nevertheless, the specific molecular mechanisms through which circRNA facilitates the progression of ESCC are still largely undefined.

methodsHere, we identified that the expression of hsa_circ_0007580 (designated circPRKCA) was markedly elevated in ESCC. Fluorescence in situ hybridization (FISH) was conducted to verify the expression, intracellular localization, and potential prognostic value of circPRKCA based on the tissue microarray. Gain- and loss-of-function assays were employed to investigate the effects of circPRKCA both in vitro and in vivo. RNA pull-down and mass spectrometry (MS) were performed to identify the proteins bound to circPRKCA. mRNA sequencing was conducted to screen the downstream target genes of circPRKCA. Furthermore, immunoprecipitation and methylated RNA immunoprecipitation (MeRIP) analysis were used to explore the regulatory mechanisms.

resultsWe found that circPRKCA exhibited significant upregulation in ESCC tissues and correlated with unfavorable prognostic outcomes. Biological function experiments further confirmed that circPRKCA enhances the capabilities of migration, invasion, and angiogenesis in ESCC. Mechanistically, circPRKCA engages in interaction with Y-box binding protein 1 (YBX1) within the cytoplasmic milieu, consequently preventing the ubiquitination-mediated degradation of YBX1. Increased concentrations of YBX1 increase the stability of granulocyte-macrophage colony-stimulating factor (CSF2) mRNA in a 5-methylcytosine (m5C)-dependent manner. This process facilitates metastasis in ESCC.

conclusionIn this research, we identified a correlation between circPRKCA and unfavorable prognoses in patients with ESCC. It is instrumental in the metastatic progression of ESCC via the YBX1/CSF2 signaling pathway. Consequently, targeting circPRKCA may represent a promising therapeutic strategy for ESCC.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaGranulocyte-Macrophage Colony-Stimulating FactorRNA, CircularRNA, MessengerRNA StabilityAnimalsCell Line, TumorCell MovementFemaleGene Expression Regulation, NeoplasticHumansMaleNeoplasm MetastasisPrognosisUp-RegulationGranulocyte-Macrophage Colony-Stimulating FactorRNA, CircularRNA, MessengerCircPRKCACSF2ESCCPrognosisYBX1

Identifiers

PMID40170133
PMCPMC11959849

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.